Literature DB >> 21685781

Apolipoprotein E ε2 and functional decline in amnestic mild cognitive impairment and Alzheimer disease.

Aaron Bonner-Jackson1, Ozioma Okonkwo, Geoffrey Tremont.   

Abstract

BACKGROUND: Recent work has demonstrated the potentially protective effects of the apolipoprotein E (APOE) ε2 allele on cognitive functioning in individuals at risk for developing Alzheimer disease. However, little is known regarding the effect of ε2 genotype on rate of change in daily functioning over time. The aim of the current study was to examine the relationship between APOE genotype and change over time in ability to perform daily activities.
METHODS: We examined the relationship between APOE genotype and change in the ability to perform activities of daily living at 12- and 24-month intervals in 225 healthy comparison subjects, 381 individuals with amnestic mild cognitive impairment, and 189 individuals with Alzheimer disease who were enrolled in the Alzheimer's Disease Neuroimaging Initiative study. Neuropsychological measures were also collected at each follow-up.
RESULTS: Overall, individuals with at least one APOE-ε2 allele showed less functional decline over time and better performance on neuropsychological measures than those without an ε2 allele, even after controlling for potential confounders. When diagnostic groups were examined individually, presence of the ε2 allele continued to be associated with slower functional decline, although the relationship was no longer statistically significant in most cases, likely due to reduced statistical power.
CONCLUSIONS: Our findings suggest that the APOE-ε2 allele provides a buffer against significant changes in daily functioning over time and is associated with better neuropsychological performance across a number of measures.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21685781      PMCID: PMC3188382          DOI: 10.1097/JGP.0b013e3182203c32

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  25 in total

1.  Prediction of functional status from neuropsychological tests in community-dwelling elderly individuals.

Authors:  D A Cahn-Weiner; P F Malloy; P A Boyle; M Marran; S Salloway
Journal:  Clin Neuropsychol       Date:  2000-05       Impact factor: 3.535

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  Executive dysfunction in Alzheimer disease.

Authors:  Margaret M Swanberg; Rochelle E Tractenberg; Richard Mohs; Leon J Thal; Jeffrey L Cummings
Journal:  Arch Neurol       Date:  2004-04

4.  Development and validation of a model for estimating premorbid verbal intelligence in the elderly.

Authors:  E Grober; M Sliwinski
Journal:  J Clin Exp Neuropsychol       Date:  1991-11       Impact factor: 2.475

5.  Cerebral atrophy, apolipoprotein E varepsilon4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment.

Authors:  Ozioma C Okonkwo; Michael L Alosco; Beth A Jerskey; Lawrence H Sweet; Brian R Ott; Geoffrey Tremont
Journal:  Alzheimers Dement       Date:  2010-09       Impact factor: 21.566

6.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

7.  Measurement of functional activities in older adults in the community.

Authors:  R I Pfeffer; T T Kurosaki; C H Harrah; J M Chance; S Filos
Journal:  J Gerontol       Date:  1982-05

8.  The apolipoprotein E epsilon 2 allele and decline in episodic memory.

Authors:  R S Wilson; J L Bienias; E Berry-Kravis; D A Evans; D A Bennett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

Review 9.  Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3.

Authors:  G William Rebeck; Mark Kindy; Mary Jo LaDu
Journal:  J Alzheimers Dis       Date:  2002-06       Impact factor: 4.472

10.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease.

Authors:  E H Corder; A M Saunders; N J Risch; W J Strittmatter; D E Schmechel; P C Gaskell; J B Rimmler; P A Locke; P M Conneally; K E Schmader
Journal:  Nat Genet       Date:  1994-06       Impact factor: 38.330

View more
  13 in total

Review 1.  Functional Disability in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.

Authors:  Cutter A Lindbergh; Rodney K Dishman; L Stephen Miller
Journal:  Neuropsychol Rev       Date:  2016-07-08       Impact factor: 7.444

2.  APOEε2 is associated with milder clinical and pathological Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Jing Qian; Sarah E Monsell; Rebecca A Betensky; Bradley T Hyman
Journal:  Ann Neurol       Date:  2015-06       Impact factor: 10.422

3.  APOE moderates the association between lifestyle activities and cognitive performance: evidence of genetic plasticity in aging.

Authors:  Shannon K Runge; Brent J Small; G Peggy McFall; Roger A Dixon
Journal:  J Int Neuropsychol Soc       Date:  2014-05       Impact factor: 2.892

Review 4.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-06       Impact factor: 21.566

5.  CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.

Authors:  Boris-Stephan Rauchmann; Thomas Schneider-Axmann; Panagiotis Alexopoulos; Robert Perneczky
Journal:  Neurobiol Aging       Date:  2018-10-25       Impact factor: 4.673

Review 6.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Li Shen; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2013-08-07       Impact factor: 21.566

7.  Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease.

Authors:  Jing Qian; Rebecca A Betensky; Bradley T Hyman; Alberto Serrano-Pozo
Journal:  Neurology       Date:  2021-03-26       Impact factor: 11.800

Review 8.  Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers.

Authors:  Li Shen; Paul M Thompson; Steven G Potkin; Lars Bertram; Lindsay A Farrer; Tatiana M Foroud; Robert C Green; Xiaolan Hu; Matthew J Huentelman; Sungeun Kim; John S K Kauwe; Qingqin Li; Enchi Liu; Fabio Macciardi; Jason H Moore; Leanne Munsie; Kwangsik Nho; Vijay K Ramanan; Shannon L Risacher; David J Stone; Shanker Swaminathan; Arthur W Toga; Michael W Weiner; Andrew J Saykin
Journal:  Brain Imaging Behav       Date:  2014-06       Impact factor: 3.978

9.  Apolipoprotein E ε4 is superior to apolipoprotein E ε2 in predicting cognitive scores over 30 months.

Authors:  Paul Regal; Balakrishnan Nair; Eileen Hetherington
Journal:  Clin Interv Aging       Date:  2013-11-01       Impact factor: 4.458

10.  Associations between apolipoprotein E gene polymorphisms and Alzheimer's disease risk in a large Chinese Han population.

Authors:  Ping Wu; Hong-Lei Li; Zhi-Jun Liu; Qing-Qing Tao; Miao Xu; Qi-Hao Guo; Zhen Hong; Yi-Min Sun
Journal:  Clin Interv Aging       Date:  2015-01-30       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.